



DURECT Corporation Presenting at The CIBC World Markets 14th Annual Healthcare Conference

CUPERTINO, Calif., Nov. 7 /PRNewswire-FirstCall/ — DURECT Corporation (Nasdaq: DRRX) announced today that it will present at the CIBC Annual Biotechnology and Specialty Pharmaceuticals Conference. The conference is being held at The Plaza Hotel in New York City. James E. Brown, DVM, Chief Executive Officer, will be presenting at the conference on Wednesday, November 12, 2003 at 11:30 a.m. EDT.

(Logo: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>)

A live audio webcast of Dr. Brown's presentation will be available by accessing DURECT's homepage at <http://www.durect.com> and clicking "Investor Relations".

About DURECT Corporation

DURECT Corporation (www.durect.com) is pioneering the development and commercialization of pharmaceutical systems for the treatment of chronic debilitating diseases and enabling biotechnology-based pharmaceutical products. DURECT's goal is to deliver the right drug to the right site in the right amount at the right time. In addition to its rights to the CHRONOGESIC product, DURECT owns three proprietary drug delivery platform technologies, including the SABER(TM) Delivery System (a patented and versatile depot injectable useful for protein delivery), the MICRODUR(TM) Biodegradable Microparticulates (microspheres injectable system) and the DURIN(TM) Biodegradable Implant (drug-loaded implant system).

NOTE: CHRONOGESIC(R), SABER(TM), MICRODUR(TM) and DURIN(TM) are trademarks of DURECT Corporation.

The statements in this press release regarding DURECT's products in development, product development plans and projected financial results are forward-looking statements involving risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, DURECT's ability to complete the design, development, and manufacturing process development of its products, manufacture and commercialize its products, obtain product and manufacturing approvals from regulatory agencies, manage its growth and expenses, manage relationships with third parties, finance its activities and operations, as well as marketplace acceptance of DURECT's products. Further information regarding these and other risks is included in DURECT's Annual Report on Form 10-K for the fiscal year ended December 31, 2002 filed with the SEC on March 14, 2003 and other periodic reports filed with the SEC under the heading "Factors that may affect future results."

CHRONOGESIC is under development by DURECT and has not been submitted or approved for commercialization by the US Food and Drug Administration or other



health authorities.

SOURCE DURECT Corporation

CONTACT:

Schond L. Greenway

Senior Director, Investor Relations and

Strategic Planning of DURECT Corporation

408-777-1417

/Photo: NewsCom: <http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO>

AP Archive: <http://photoarchive.ap.org>

PRN Photo Desk, +1-888-776-6555 or +1-212-782-2840

/Web site: <http://www.durect.com>